Epitranscriptomic Regulation of ALDOA by SHMT2-Mediated m6A Modification Drives Gastric Cancer Malignancy.
Targeting the SHMT2-ALDOA axis represents a promising therapeutic strategy for gastric cancer by enhancing ALDOA expression through m6A modification and IGF2BP1-mediated stabilization.